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Nitric oxide (NO), synthesized enzymatically by nitric oxide
synthases (NOS), has been shown to regulate vascular tone,
central and peripheral nervous system signal transmission, and
cell-mediated cytotoxicity (Moncada et al, 1991). Based on
calcium dependence, three different NOS isoforms have been
identified in human tissues: endothelial NOS (eNOS), neuronal
NOS (nNOS), both of which are calcium dependent, and inducible
NOS (iNOS), which is calcium independent. iNOS is transcrip-
tionally regulated by a variety of growth factors and inflammatory
cytokines, such as tumour necrosis factor a (TNF-a), interleukin 1
(IL-1),  g-interferon (IFN-g), and bacterial lipopolysaccharide
(LPS) (Moncada et al, 1991; Nathan et al, 1994). The induction of
iNOS results in the production of high levels of NO, which is
associated with a cytotoxic reaction mainly against pathogens
(Schmidt and Walter, 1994). The role of NO in tumour biology,
however, is still poorly understood. In situ studies have revealed
that NOS expression is present in the tumour cells of solid human
tumours (Thomsen et al, 1994). It has also been shown to be
expressed in stromal cells of human breast carcinomas (Thomsen
et al, 1995). Moreover, iNOS expression was shown in cultured
K-1735 murine melanoma cells after appropriate stimulation with
a combination of cytokines (Dong et al, 1994). However, its pres-
ence in situ in human malignant melanoma has not been reported.
In the present study, we addressed this issue and investigated
expression and cellular localization of NOS isoforms in human
subcutaneous and lymph node melanoma metastases. Data on
iNOS expression in these tissues were then correlated with both
the potential of tumours to form distant metastases and the
patients’ survival time.
MATERIALS AND METHODS
Patients
Subcutaneous or lymph node melanoma metastases (stage II–IV
according to the UICC criteria) were obtained from 22 patients
after informed consent. The specimens were divided and one part
was fixed in neutral-buffered formalin for histological diagnosis
(H and E histology), the other portion was snap frozen and stored
at –80°C for subsequent immunolabelling and Western blot
analysis. Tumour-free axillary lymph nodes of breast cancer
patients were used as additional controls. Twelve of these 22
patients did not develop distant metastases during an observation
period of 3 years (group 1), whereas the remaining ten patients
developed lung, liver or brain metastases within 3–14 months
(group 2). Four patients of group 1 and three patients of group 2
were women, the other patients were men.
Immunohistochemistry
Immunohistochemistry was carried out as previously described
(Tschugguel et al, 1996). In brief, the following antibodies were
used on 6-mm frozen serial sections: murine monoclonal anti-
bodies against human eNOS (2.5 mg ml–1) and iNOS (5 mg ml–1)
(both were from Transduction Laboratories, Lexington, KY,
USA), a rabbit polyclonal antibody against rat brain nNOS
synthetic peptide (1:4000 dilution) (Biomol, Plymouth, PA, USA),
a monoclonal HMB45 antibody or a polyclonal S-100 antiserum
for identification of melanoma cells (respective dilutions were
1:100 and 1:200) (Dako, Glostrup, Denmark), and a polyclonal
von Willebrand factor antibody (1:200 dilution) (Bio Genex, San
Ramon, CA, USA). For leucocyte detection, adjacent sections
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Correspondence to: W Tschugguelwere incubated with a monoclonal antibody against the human
leucocyte marker CD45 (Bio Genex) at 1:40 dilution. Negative
controls were applied for all tissue sections by replacement of
primary antibodies with appropriately diluted isotype-specific
irrelevant immunoglobulins.
For immunohistochemistry, the slides were examined in a blind
fashion by four independent observers (WT, TP, HL and WW).
Quantification of iNOS+ cells and statistical analysis
Quantitative studies were carried out on sections stained with the
monoclonal iNOS antibody. The number of tumour cells recog-
nized as positively stained by this antibody was counted in three
random and consecutive high-power fields with a ´ 40 objective,
and expressed as a percentage of the total number of tumour cells
counted in the same area.
The mean and the standard deviation of the number of iNOS+
cells from patients within groups 1 and 2 were calculated. The
Wilcoxon statistical test was used to test the differences in the
number of iNOS+ cells between both groups. Moreover, differ-
ences in survival times within a clinical follow-up time of 3 years
were tested using the Cox regression model. Differences were
considered significant when P < 0.05.
Western blot analysis
For the analysis of iNOS protein expression, samples of frozen
lymph nodes (melanoma lymph node metastases of group 1
patients,  n = 2, and group 2 patients, n = 3; controls from axilla,
n = 3) were homogenized and then lysed in NP40 lysis buffer as
described previously (Pammer et al, 1996). After quantification,
proteins were electrophoresed and blotted with an anti-iNOS
monoclonal antibody (1.25 mg ml–1) (Transduction Laboratories)
or an appropriately diluted isotype matched IgG2a control mono-
clonal antibody. This was followed by an HRP-conjugated sheep
anti-mouse antibody (1:10 000). Specific reaction products were
detected by chemoluminescence (ECL-kit, Amersham).
RESULTS
Immunohistochemistry was performed on 25 tissue samples
consisting of six subcutaneous and 16 lymph node metastases of
malignant melanomas and three tumour-free axillary lymph nodes.
Melanoma cells were identified by staining against HMB45 or
S-100 protein (data not shown).
The results of iNOS immunostaining and its association with
the patients’ outcome are summarized in Table 1. Immunostaining
for iNOS was most pronounced in group 1 samples (subcutaneous
or lymph node metastases of malignant melanoma, no distant
metastases; n = 12) (Figure 1A), of which a respective H and E
staining is presented (Figure 1B). In these samples, 55% ± 17% of
the melanoma cells contained iNOS. The iNOS-containing tumour
cells were found dispersely distributed throughout the tumour (not
shown) or appeared to be a distinct population within solid tumour
islands (Figure 1A). In contrast, cells positive for the human
leucocyte antigen CD45 (Figure 1C) were restricted to the tumour
stroma and appeared to be consistently iNOS negative. iNOS+
melanoma cells and unstained neighbouring melanoma cells did
not differ in cell morphology. The intensity of staining within indi-
vidual cells varied. Control sections with the IgG2a isotype control
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Table 1 Association between clinical follow-up data and percentage of iNOS+ cells per high-power field
(HPF) at time of surgery. Statistical analysis is described in the Results section
Patient Age at time Tissuea Distant Survival time %iNOS+
of biopsy metastasesb in months cells/HPF
Group 1
DE 89 s.c. – Alive 30
GJ 78 s.c. – Alive 60
AI 64 l.n. – Alive 50
BK 59 l.n. – Alive 40
HJ 78 l.n. – Alive 80
SF 71 s.c. – Alive 40
GH 74 s.c. – Alive 45
WK 79 l.n. – Alive 70
KA 78 l.n. – Alive 60
VE 41 l.n. – Alive 40
SH 56 l.n. – Alive 85
KJ 47 l.n. – Alive 60
Group 2
SR 86 s.c. 6 8 0
SK 54 s.c. 12 13 0
BF 87 l.n. 11 Alive 5
KG 65 l.n. 10 18 5
TJ 72 l.n. 7 Alive 10
ST 58 l.n. 13 18 0
RF 57 l.n. 13 Alive 15
WM 49 l.n. 2 Alive 10
AG 58 l.n. 5 7 20
PT 87 l.n. 2 3 25
aTissue: s.c., subcutaneous metastasis; l.n., lymph node metastasis. bTime in months until occurrence of
distant metastases (–, no distant metastases)antibody showed no specific staining (data not shown). Group 2
samples (subcutaneous or lymph node metastases of malignant
melanoma, formation of distant metastases within 2–13 months; 
n = 10) had significantly fewer iNOS+ tumour cells (9% ± 8%)
(Figure 2A) compared with group 1 samples (P < 0.001).
Moreover, in group 2 samples, scarce CD45+ cells were inter-
mingled between other unstained stroma cells (Figure 2B). Using
the Cox regression model, no association was found between the
number of iNOS+ tumour cells and cumulative survival (P =
0.0707). In axillary lymph node samples (n = 3), no iNOS staining
could be detected (not shown). The specificity of the immuno-
histochemistry results was confirmed by Western blotting of select
cases (Figure 3). We also excluded crossreactivity of the iNOS
antibody with eNOS and nNOS antigens and demonstrated that
eNOS staining was restricted to vascular endothelial cells (data not
shown). eNOS staining furthermore corresponded to the distribu-
tion of von Willebrand factor. nNOS staining was not detectable in
any of the lesions (data not shown).
DISCUSSION
Our finding that iNOS expression may be negatively correlated
with metastatic potential is in accordance with findings by Dong et
al (1996), who demonstrated that non-metastatic K-1735 murine
melanoma cells exhibited high levels of iNOS activity and NO
release whereas metastatic cells did not. An inverse association
between production of endogenous NO and the ability of K-1735
cells to survive in syngeneic mice to produce lung metastases was
shown (Dong et al, 1996). Moreover, transfection of highly
metastatic K-1735 cells, which express low levels of iNOS, with
an iNOS expression vector rendered the cells non-metastatic by
inducing high levels of NO production (Xie et al, 1995). These
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Figure 1 Serial sections of a melanoma lymph node metastasis from
patient ‘GJ’ of group 1 (subcutaneous or lymph node metastases of
malignant melanoma, no distant metastases). (A) iNOS immunostaining is
present within the majority of the tumour cells, which are localized among
other unstained tumour cells (bar, 16 mm); (B) H and E histology (bar, 64 mm);
(C) antigen localization with the CD45 antibody reveals that abundant CD45+
cells are localized within the stroma (bar, 16 mm); The arrows in (A), (B) and
(C) indicate the border between tumour cells and stroma
A
B
Figure 2 Melanoma lymph node metastasis from patient ‘KG’ of group 2
(subcutaneous or lymph node metastases of malignant melanoma, formation
of distant metastases within 3–14 months). (A) Note that only a few iNOS
immunoreactive tumour cells (arrows) are intermingled between the majority
of unstained tumour cells (bar, 16 mm); (B) antigen localization with the CD45
antibody reveals that scarce CD45+ cells (arrows) are localized within the
stroma (bar, 16 mm)murine data as well as our results obtained in melanoma patients
show an inverse correlation between iNOS expression and the
ability of tumours to form distant metastases. Our findings suggest
a significant inhibitory effect of tumour cell-derived NO on
metastasis formation in human malignant melanomas.
Programmed cell death (apoptosis) is recognized as one of the
main homeostatic mechanisms designed to block metastatic
dissemination. Nitric oxide, a potent stimulus of apoptosis induc-
tion in K-1735 melanoma cells (Xie et al, 1996) has been reported
to mediate apoptosis via expression of wild-type tumour-
suppressor protein p53 (Meßmer et al, 1994). Accordingly, when
the latter cells were transfected with mutant p53 cDNAs, they
became metastatic, whereas parent and control-transfected cells
remained non-metastatic (Koura et al, 1997). Additionally, nitric
oxide-induced apoptosis in these cells is associated with down-
regulation of Bcl-2, a proto-oncogene product that promotes cell
survival and inhibition of apoptosis in various cells (Xie et al,
1997). In view of these considerations, we hypothesize that
inducibly released nitric oxide may suppress the metastatic poten-
tial of human melanoma cells via induction of apoptosis. However,
no significant correlation between the number of iNOS+ tumour
cells and the survival time of patients could be seen. This may be
caused by too short an observation time or our small sample size.
Notably, however, we could demonstrate that inducible nitric
oxide synthase (iNOS) expression in human subcutaneous or
lymph node melanoma metastasis seems to be inversely correlated
with the tumour’s ability to form distant metastases.
ACKNOWLEDGEMENTS
We are grateful to Helga Herre and Ladislaus Szabó for excellent
technical assistance and helpful methodical discussions. The study
was supported in part by Schering Wien GesmbH., Vienna,
Austria.
REFERENCES
Dong Z, Staroselsky AH, Qi X, Xie K and Fidler IJ (1994) Inverse correlation
between expression of inducible nitric oxide synthase activity and production
of metastases in K-1735 murine melanoma cells. Cancer Res 54: 789–793
Koura AN, VanGolen K, Tsan R, Radinsky R, Price JE and Ellis LM (1997)
Regulation of genes associated with angiogenesis, growth, and metastasis by
specific p53 point mutations in a murine melanoma cell line. Oncol Rep 4:
475–479
Meßmer UK, Ankarcrona M, Nicotera P and Brüne B (1994) p53 expression in
nitric oxide-induced apoptosis. FEBS Lett 355: 23–26
Moncada S, Palmer RMJ and Higgs EA (1991) Nitric oxide: physiology,
pathophysiology, and pharmacology. Pharmacol Rev 43: 109–142
Nathan C and Xie QW (1994) Regulation of biosynthesis of nitric oxide. J Biol
Chem 269: 13725–13728
Schmidt HHHW and Walter U (1994) NO at work. Cell 78: 919–925
Pammer J, Plettenberg A, Weninger W, Diller B, Mildner M, Uthman A, Issing W,
Stürzl M and Tschachler E (1996) CD40 antigen is expressed by endothelial
cells and tumor cells in Kaposi’s sarcoma. Am J Pathol 148: 1387–1396
Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V and
Moncada S (1994) Nitric oxide synthase activity in human gynecological
cancer. Cancer Res 54: 1352–1354
Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S
(1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:
41–44
Tschugguel W, Knogler W, Czerwenka K, Mildner M, Weninger W, Zeillinger R and
Huber JC (1996) Presence of endothelial calcium-dependent nitric oxide
synthase in breast apocrine metaplasia. Br J Cancer 74: 1423–1426
Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C and Fidler IJ
(1995) Transfection with the inducible nitric oxide synthase gene suppresses
tumorigenicity and abrogates metastases by K-1735 murine melanoma cells. 
J Exp Med 181: 1333–1343
Xie K, Dong Z and Fidler IJ (1996) Activation of nitric oxide synthase gene for
inhibition of cancer metastasis. J Leukoc Biol 59: 797–803
Xie K, Wang YF, Huang SY, Xu L, Bielenberg D, Salas T, McConkey DJ, Jiang WD
and Fidler IJ (1997) Nitric oxide mediated apoptosis of K 1735 melanoma cells
is associated with downregulation of Bcl 2. Oncogene 15: 771–779
1612 W Tschugguel et al
British Journal of Cancer (1999) 79(9/10), 1609–1612 © Cancer Research Campaign 1999
1234567891 0
1234567891 0
kDa
- 200 -
- 98 -
- 68 -
- 46 -
- 31 -
- 21 -
- 15 -
kDa
- 200 -
- 98 -
- 68 -
- 46 -
- 31 -
- 21 -
- 15 -
A
B
Figure 3 Western blot analysis of iNOS expression (A) and respective
negative controls with an isotype control antibody (IgG2a) (B) were
performed on the following extracts: tumour-free axillary lymph nodes of two
control patients (lanes 3 and 4) and malignant lymph nodes from patients
‘HJ’ (lane 5), ‘GJ’ (lane 6) and ‘AI’ (lane 7) of group 1, and of patients ‘SR’
(lane 8), ‘SK’ (lane 9) and ‘ST’ (lane 10) of group 2; a mouse macrophage
lysate treated with IFN-g and LPS for 12 h (transduction) was used as a
positive control (lane 1) and an extract of human umbilical vein endothelial
cells was used as a negative control (lane 2); an arrow indicates a 130-kDa
specific band corresponding to iNOS in lanes 1, 5, 6 and 7 of A. Relative
iNOS protein amounts were quantified by densitometric scanning and
expressed by taking the IFN-g and LPS-treated mouse macrophage lysate
value as 1.0 (lane 1). This calculation revealed that the relative iNOS
induction was 0.37-fold in lane 5, 0.23 in lane 6 and 0.16 in lane 7 compared
with no such induction in lanes 8, 9 and 10